ENVB - CIK 0000890821
The table below shows Enveric Biosciences, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$2.26M | -$2.39M | -$2.60M | -$5.14M | -$4.55M | -$3.16M |
| Capital expenditure | - | - | - | $5.17K | $505.51K | - |
| Investing cash flow | - | - | - | -$5.17K | -$505.51K | -$675.00K |
| Dividends paid | - | - | - | - | - |
Enveric Biosciences, Inc. reported operating cash flow of -$8.14M for fiscal year 2025. That is down 5.4% from -$7.73M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$2.70M (FY 2016) to -$8.14M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $2.50M | $4.45M | $6.66M | - | $9.40M | $24.88M |